TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Exercise Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of abnormal glucose regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CT-Scan evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of solicited symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of unsolicited symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: 3-year relapse rate
Endpoint domain: Mortality/survival
Primary endpoint: Seroprevalence of viral hepatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Kinematic gait parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of children who remain well-nourished
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of local and systemic adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Color Trails Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Falls Self-Efficacy Scale-International (FES-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fall Behavioral (FAB) Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Early functional outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 28-Day All Cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Any Drinking Days in Previous Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any Heavy Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any Cocaine Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carboxymethyl lysine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pentosidine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility of cryoablation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety of cryoablation procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Change in strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Abnormal RBC Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Family Empowerment Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Duke-UNC Functional Social Support Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Youth Services Survey for Families
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Very good partial response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parastomal hernia rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Active device performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RDP Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall survival of patients
Endpoint domain: Mortality/survival
Primary endpoint: Change over time of quality of life from diagnosis until end of active treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pharmacokinetics of paliperidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: recommended phase II dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of sexually transmitted infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Ocular Surface Disease Index Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Median Cervical Mucus Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Sperm Penetration Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Time to negatively RT-PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Listening Inventory For Education Revised (LIFE-R) - Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Listening in Spatialised Noise - Sentences Test (LiSN-S) - Low-cue Speech Reception Threshold Condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Listening in Spatialised Noise - Sentences Test (LiSN-S) - High-cue Speech Reception Threshold Condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of New BCCs Per Participant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Two-point Discrimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in N20 Somatosensory Evoked Potential(SSEP) Peak Latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivities and Specificity for diagnosis of sleep apnoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Absolute change from Baseline in inflammatory lesion counts at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change from Baseline in non-inflammatory lesion counts at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator's Global Assessment (IGA) Treatment Success at Week 12
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of complete tumor ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: serum level of tryptase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of colonization in tracheal aspirates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in the level of DNA methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immune inflammation-related protein complexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: blood markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants Achieving a SRI Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Non-serious Adverse Events (nSAEs) and Serious Adverse Event (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Morphological embryo quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and toxicity of Erbitux treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Morning pre-dose PEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of study participants successfully completing all modules of the MSPT device
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percent (%) of study participants successfully completing all modules of the MSPT device
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Pain Presence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of upper limb function in the body function and structure level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of upper limb function in the activity level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent inhibition of CXCL1-induced CD11b expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time in Bed
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Delta PVI to Delta LAP Correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment Failure Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of progression-free events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tobacco smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in level of physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in diet quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time taken for the completion of oral rehabilitation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tumoral volumetric size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in mean maximum intima media thickness (IMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial T2* values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correlation between pain biomarker and Numeric Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in accuracy on the CANTAB Spatial Working Memory Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Parents' satisfaction with the informed consent process
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The parent's knowledge of ketamine sedation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Occurrence of E. coli associated with sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of S. aureus bacteremia associated with sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: Successful visual acuity outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Labor length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Changes in American orthopaedic foot and ankle society (AOFAS) ankle-hindfoot score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Short form 12 (SF 12)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent of Patients Who Achieved HbA1c ≤ 7.4%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Minimal Weight Gain (≤ 1kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of all adverse events (AEs) / serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean difference in ECG heart rate (HR) nadir values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nadir absolute lymphocyte count (ALC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in vaccine awareness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nominal change of percent atheroma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MACCE (Death, Myocardial Infarction or Stroke)
Endpoint domain: Mortality/survival
Primary endpoint: Definite or Probable Stent Thrombosis (ST)
Endpoint domain: Adverse events/effects
Primary endpoint: GUSTO Severe or Moderate Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: New Acquisition of Serotype 6A or 19A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to Maximum Observed Plasma Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve from time zero to last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Who Required a Revision of the Index Surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Ocular Surface Temperature (OST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Area under curve (AUC) of edaravone in single dose groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under curve (AUC) of edaravone in multiple doses group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of edaravone in single dose groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of edaravone in multiple doses group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Polysomnographic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coagulopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Long Term Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Increase of corneal transparency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in macular thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL6 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Monocular Photopic Best Corrected Distance Visual Acuity (5 m)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocular Photopic Distance Corrected Intermediate Visual Acuity (60 cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocular Photopic Distance Corrected Near Visual Acuity (40 cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain during sheath insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion converted to femoral access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Successful Techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Success of the Technique at the First Attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Attempts Required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Documented recurrence of atrial fibrillation or any atrial tachyarrhythmia >30 seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with Treatment Emergent Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Abnormalities in Vital Signs, Physical Examinations, Electrocardiogram (ECG), Cardiac Telemetry and Clinically Significant Laboratory Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of hypocalcaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MSC identification using MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic Response Rate (RRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPV-measured cost difference
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CPV-measured clinical score difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: evolution of blood markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in CAARS questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Monocular Distance Corrected Intermediate Visual Acuity (DCIVA) at 67 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sternal bone healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in mRS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombosis (total thrombus formation analysis system)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prognostic score of overall survival (OS)
Endpoint domain: Mortality/survival
Primary endpoint: Size of halo detected on ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: dynamic changes of serum sTREM-1 and MNDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Viral Response (SVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Self-reported unprotected anal or vaginal sex
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom From Documented Symptomatic Atrial Fibrillation, Atrial Tachycardia, or Atrial Flutter Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Virologic Response at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous activity in peripheral c-nociceptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gaps Days Between Prescription Refills
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline of the Lactose Intolerance symptom composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting Blood Sugar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in pulmonary electric impedance tomography (EIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in PaO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood Glucose Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean of number of positive SpA features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with image examination of sacroiliitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with assessment of disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed Thromboembolic Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Composite of Objectively Verified Thromboembolic Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Concentrations of growth factors and inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Genotype analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen concentration in the oropharynx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline in serum CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Pocket Depth (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Clinical Attachment Level (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Curve (AUC[0-336]) for Dulaglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) for Dulaglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brachial Artery Flow-mediated Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quantitative EEG Recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: One Year Relapse Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in Median Total New Lesion Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Patients With Major Adverse Cardiac and Cerebrovascular Events (MACCE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who complete study sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention